Novo Nordisk Inc v. Mylan Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Mylan Pharmaceuticals Inc. (West Virginia)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:24-cv-00775, D. Del., 07/01/2024
• Venue Allegations: The complaint alleges that Defendant Mylan Pharmaceuticals Inc. has agreed not to contest personal jurisdiction or venue in the District of Delaware for this action.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for a generic version of the diabetes drug Ozempic® constitutes an act of infringement of two patents covering the active ingredient, semaglutide, and its method of use.
• Technical Context: The technology involves long-acting GLP-1 receptor agonists, a major class of pharmaceutical compounds used for the treatment of type 2 diabetes and obesity.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter, dated May 22, 2024, in which Defendant Mylan informed Plaintiff that it had filed an ANDA with a Paragraph IV certification, asserting that Plaintiff's patents are invalid, unenforceable, and/or will not be infringed by its proposed generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,129,343 - "Acylated GLP-1 Compounds" (issued March 6, 2012)

The Invention Explained

• Problem Addressed: The patent addresses the short in-vivo half-life of naturally occurring glucagon-like peptide 1 (GLP-1) compounds, which limits their therapeutic utility by requiring frequent injections for patients with diabetes Compl. ¶10 '343 Patent, col. 1:17-25
• The Patented Solution: The invention describes chemically modified GLP-1 analogs that are "acylated," meaning a specific side chain containing at least two acidic groups is attached to the peptide. This modification is designed to promote binding to albumin in the bloodstream, thereby extending the compound's duration of action and allowing for less frequent dosing '343 Patent, col. 2:1-6 The compound known as semaglutide is a primary embodiment of this invention '343 Patent, col. 61:25-62:26, Example 4
• Technical Importance: The development of long-acting GLP-1 analogs represented a significant advance in diabetes management by improving patient convenience and adherence to therapy.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 Compl. ¶20 Independent claims 1, 3, and 4 are asserted.
• Independent Claim 1 (Composition of Matter): A compound defined by a specific chemical structure (Formula I) comprising:
  • A GLP-1 peptide backbone (Xaa₇-Xaa₃₈) with specific amino acid substitutions relative to native GLP-1.
  • An acylated moiety (B-U') attached to a lysine residue.
  • The acylated moiety includes a linker (U') and a terminal acidic group (B).
• The complaint reserves the right to assert dependent claims Compl. ¶20

U.S. Patent No. 10,335,462 - "Use of Long-Acting GLP-1 Peptides" (issued July 2, 2019)

The Invention Explained

• Problem Addressed: The patent's background discusses the need for improved therapeutic regimens for long-acting GLP-1 agonists to treat conditions such as type 2 diabetes and obesity '462 Patent, col. 2:51-56
• The Patented Solution: The invention claims specific methods of treatment using the long-acting GLP-1 peptide semaglutide. The core of the patented solution is the administration of a specific dose of semaglutide on a specific schedule to achieve a desired therapeutic outcome, such as the reduction of HbA1c levels in diabetic patients '462 Patent, abstract '462 Patent, col. 1:30-43 The patent's figures illustrate the dose-dependent reduction in HbA1c and body weight achieved with semaglutide '462 Patent, Fig. 1 '462 Patent, Fig. 5
• Technical Importance: Establishing an optimal and effective dosing schedule is a critical component of pharmaceutical development, directly impacting a drug's efficacy and safety profile.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-10 Compl. ¶27 Independent claim 1 is asserted.
• Independent Claim 1 (Method of Treatment): A method for treating type 2 diabetes, comprising the following steps:
  • Administering semaglutide.
  • To a subject in need thereof.
  • The administration is performed once weekly.
  • The administration is in an amount of 1.0 mg.
• The complaint reserves the right to assert dependent claims Compl. ¶27

III. The Accused Instrumentality

Product Identification

• Mylan's proposed generic version of semaglutide injection, 2 mg/3 mL (0.68 mg/mL), which is the subject of Abbreviated New Drug Application (ANDA) No. 219255 Compl. ¶15

Functionality and Market Context

• The complaint alleges that Mylan's product contains semaglutide as its active pharmaceutical ingredient and is intended to be a generic equivalent of Novo Nordisk's Ozempic® Compl. ¶15
• As an ANDA product, Mylan's product relies on the safety and efficacy data of Ozempic® and is alleged to be bioequivalent Compl. ¶16 Ozempic® is a widely prescribed medication for the treatment of type 2 diabetes, and the complaint positions Mylan's product as a direct generic competitor Compl. ¶1 Compl. ¶14
• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The infringement allegations are made under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA seeking approval to market a drug claimed in a patent before its expiration as an act of infringement Compl. ¶19 Compl. ¶26

'343 Patent Infringement Allegations

The complaint does not provide sufficient detail for a full claim chart analysis. The core allegation is that Mylan's product is semaglutide, and therefore its chemical structure literally infringes the asserted claims covering the compound Compl. ¶20 For an ANDA product to be approved as a generic, it must contain the same active ingredient as the reference listed drug. The central dispute on this patent may therefore focus more on validity challenges than on non-infringement.

'462 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: For the '462 Patent, a primary question will be whether Mylan's proposed product label will instruct, encourage, or inevitably lead to the administration of semaglutide "once weekly" and "in an amount of 1.0 mg" for the treatment of type 2 diabetes. The complaint does not contain Mylan's proposed label, making this a central issue for discovery.
• Technical Questions: For the '343 Patent, the infringement analysis will likely turn on a direct comparison of the chemical structure of Mylan's active ingredient with the structures claimed in the patent. As Mylan seeks approval for a generic version of semaglutide, any non-infringement argument would have to contend with the fact that the patent explicitly claims and describes semaglutide. The dispute may therefore shift to validity challenges, such as obviousness or lack of enablement, as foreshadowed in the complaint's reference to Mylan's Paragraph IV letter Compl. ¶17

V. Key Claim Terms for Construction

Term: "administering... in an amount of 1.0 mg" (['462 Patent, claim 1](https://ex:cit:20))

• Context and Importance: This term is critical because the patentability of the method claim may rest on the specificity of the dosage regimen. Infringement will depend on whether Mylan's proposed label instructs this exact dose. Practitioners may focus on this term because if it is construed narrowly to mean exactly 1.0 mg, Mylan could potentially design a label that omits this specific dose to avoid literal infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes clinical trials with a range of doses, such as 0.8 mg and 1.6 mg, and discusses dose-dependent effects '462 Patent, col. 21:5-22:40 '462 Patent, Fig. 1 A party could argue that, in this context, "1.0 mg" should be understood to cover standard therapeutic amounts that are approximately 1.0 mg or part of a titration schedule that includes this dose.
  • Evidence for a Narrower Interpretation: The claim language is precise and recites a specific numerical value without qualifying language like "about" or "approximately." A party could argue that the patentee deliberately chose this exact amount to distinguish the invention from the prior art and is therefore bound to a narrow construction '462 Patent, claim 1

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Mylan will induce infringement of the method claims of both patents Compl. ¶21 Compl. ¶28 The alleged basis for inducement is Mylan's intent to commercially market its generic product with a label that will instruct physicians and patients to use the infringing compound in the claimed manner for treating type 2 diabetes.
• Willful Infringement: The complaint alleges that Mylan was "aware" of the patents-in-suit when it submitted its ANDA, as evidenced by its Paragraph IV certification Compl. ¶24 Compl. ¶31 This alleged pre-suit knowledge forms the basis for the willfulness claim and the request for a finding that the case is "exceptional" under 35 U.S.C. § 285.

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of validity: As is common in ANDA litigation, the case will likely focus heavily on Defendant's counterclaims that the '343 and '462 patents are invalid for reasons such as obviousness or lack of written description, which were asserted in its Paragraph IV letter. For the '343 patent, this may be the primary defense.
• A key evidentiary question will be one of label-based inducement: For the '462 method-of-use patent, the dispute will turn on the specific text of Mylan's proposed product label. Does the label explicitly instruct or implicitly encourage clinicians to "administer[] semaglutide once weekly in an amount of 1.0 mg," or does it provide a basis to argue that this claimed method is not being induced?
• A core issue will be one of claim construction: The interpretation of the dosage limitation "in an amount of 1.0 mg" in the '462 patent will be critical. The court's decision on whether this term requires exactness or allows for some flexibility could determine the outcome of the infringement analysis for the method-of-use claims.